Diabetes deaths in the United States continue to surge well above pre-pandemic levels with over 100,000 Americans dying from diabetes in 2021. Increasing deaths from diabetes is a clear call to action for new solutions. Historically, diabetes has been treated as a chronic disease, managed with a lifetime of medications. However, a new line of thinking about diabetes remission permeates the literature.
A rule slated to take effect January 1, 2023 would reverse CMS’ long held position that manufacturer-provided assistance given to patients is excluded from best price and average manufacturer price calculation for prescription drugs. The rule change could potentially result in increased patient out-of-pocket costs for drugs and pharma companies being on the hook for ensuring they know exactly where their assistance is going.
Modern technology allows for the mass collection of digital health data. Artificial intelligence has become a vital tool for making sense of the huge volume of health data being collected daily through the use of big data analytics (BDA).
Want to know the optimal strategies for negotiating pricing and formularies, and how the industry is adjusting to the continued push toward value-based models? Precision’s Ryan Cox and other experts weigh in.
CMS’s stance has long been that manufacturer-provided assistance given to patients is excluded from best price and average manufacturer price calculation for prescription drugs. However, the rise of copayment accumulators and maximizers and health insurers’ subsequent taking of this assistance rather than allowing it to count toward patients’ deductibles and out-of-pocket maximums have caused the agency to rethink its position. Precision’s Ryan Cox and Reta Mourad break down the implications of the proposed rule change, including the potential for increased patient out-of-pocket drug costs, pharma companies being on the hook for ensuring they know exactly where their assistance is going, and possible unintended consequences.
PRECISIONxtract announces the addition of two senior executives as it launches its digital data tool OncoGenius. Bruce Edelen will step into the role of SVP, OncoGenius franchise lead and Ron Schleif will serve as SVP, oncology provider group management and survey operations.
Over the last decade, healthcare costs have continued to rise in the United States while outcomes have been stagnant and, in some cases, declined. Implementation of strategies around patient- or consumer-driven care has been a struggle as stakeholders try to define, measure, and improve the patient experience.
Pre-pandemic cancer death rates were trending downward at an encouraging rate. However, global instability from COVID-19 has resulted in disruption to vital cancer screenings and treatment.
The American Rescue Plan of 2021 introduced a provision to remove the Medicaid Rebate Cap of 100%, effective January 2024. This legislation may turn profits upside down for a pharmaceutical company with a significant presence. Precision’s Cynthia Miller discusses what it would mean to remove the Medicaid Rebate Cap, how it would affect pharmaceutical companies, and strategies for moving forward.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
